Orexo Management

Management criteria checks 2/4

Orexo's CEO is Nikolaj Sorensen, appointed in Feb 2013, has a tenure of 11.17 years. total yearly compensation is SEK6.12M, comprised of 59.5% salary and 40.5% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth €222.18K. The average tenure of the management team and the board of directors is 5.3 years and 4 years respectively.

Key information

Nikolaj Sorensen

Chief executive officer

kr6.1m

Total compensation

CEO salary percentage	59.5%
CEO tenure	11.2yrs
CEO ownership	0.4%
Management average tenure	5.3yrs
Board average tenure	4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Nikolaj Sorensen's remuneration changed compared to Orexo's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	kr6m	kr4m	-kr128m
Sep 30 2023	n/a	n/a	-kr201m
Jun 30 2023	n/a	n/a	-kr195m
Mar 31 2023	n/a	n/a	-kr218m
Dec 31 2022	kr6m	kr4m	-kr178m
Sep 30 2022	n/a	n/a	-kr152m
Jun 30 2022	n/a	n/a	-kr177m
Mar 31 2022	n/a	n/a	-kr216m
Dec 31 2021	kr10m	kr4m	-kr223m
Sep 30 2021	n/a	n/a	-kr207m
Jun 30 2021	n/a	n/a	-kr240m
Mar 31 2021	n/a	n/a	-kr198m
Dec 31 2020	kr9m	kr3m	-kr84m
Sep 30 2020	n/a	n/a	kr4m
Jun 30 2020	n/a	n/a	kr201m
Mar 31 2020	n/a	n/a	kr288m
Dec 31 2019	kr6m	kr3m	kr219m
Sep 30 2019	n/a	n/a	kr232m
Jun 30 2019	n/a	n/a	kr182m
Mar 31 2019	n/a	n/a	kr178m
Dec 31 2018	kr5m	kr3m	kr138m
Sep 30 2018	n/a	n/a	kr113m
Jun 30 2018	n/a	n/a	kr79m
Mar 31 2018	n/a	n/a	kr32m
Dec 31 2017	kr6m	kr4m	kr23m

Compensation vs Market: Nikolaj's total compensation ($USD555.19K) is above average for companies of similar size in the German market ($USD402.43K).

Compensation vs Earnings: Nikolaj's compensation has increased whilst the company is unprofitable.

CEO

Nikolaj Sorensen (51 yo)

11.2yrs

Tenure

kr6,118,000

Compensation

Mr. Nikolaj Sørensen serves as Independent Director at Bioservo Technologies AB (publ) since May 6, 2019. He is Director at Gesynta Pharma AB. He has been the Chief Executive Officer of Orexo AB since Febr...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Nikolaj Sorensen	President & CEO	11.2yrs	kr6.12m	0.45% SEK 222.2k
Fredrik Jarrsten	Executive VP & CFO	1.7yrs	no data	0.076% SEK 37.6k
Cecilia Coupland	Senior VP & Head of Operations	5.3yrs	no data	0.042% SEK 20.7k
Lena Wange	Investor Relations & Communications Director	no data	no data	no data
Robert Ronn	Senior VP and Head of R&D	5.3yrs	no data	0.048% SEK 23.8k
Edward Kim	Chief Medical Officer	1.5yrs	no data	no data
Robert Deluca	President of Orexo US Inc	11.3yrs	no data	0.027% SEK 13.5k
Jesper Lind	Advisor	no data	no data	no data

5.3yrs

Average Tenure

53.5yo

Average Age

Experienced Management: C5G's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
George Wilkinson	Independent Director	5yrs	kr400.00k	0.059% SEK 29.3k
James Noble	Independent Chairman of the Board	4yrs	kr1.50m	0.15% SEK 73.9k
Staffan Lindstrand	Independent Director	22.3yrs	kr450.00k	0.090% SEK 44.3k
Christine Rankin	Independent Director	2yrs	kr550.00k	0.016% SEK 8.0k
Robin Evers	Independent Director	less than a year	kr50.00k	no data

4.0yrs

Average Tenure

61yo

Average Age

Experienced Board: C5G's board of directors are considered experienced (4 years average tenure).

Orexo Management

Management criteria checks 2/4

Key information

Recent management updates

Orexo AB (Publ) Announces Board Resignations

Orexo AB (publ) Announces Changes in the Board of Directors

Orexo AB (publ), Annual General Meeting, Apr 26, 2024

Orexo AB (Publ) Announces Henrik Kjær Hansen Will Resign from the Board of Directors

Orexo AB (publ) Appoints Edward Kim, M.D., as New Chief Medical Officer

Orexo AB (publ), Annual General Meeting, Apr 18, 2023

Recent updates

Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US

Full year 2023 earnings released: kr3.73 loss per share (vs kr5.17 loss in FY 2022)

Orexo AB (Publ) Announces Board Resignations

New major risk - Financial position

Full year 2023 earnings released: kr3.73 loss per share (vs kr5.17 loss in FY 2022)

Orexo AB (publ) to Report Q4, 2024 Results on Feb 06, 2025

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

No longer forecast to breakeven

Third quarter 2023 earnings released

Orexo AB (publ) Announces Changes in the Board of Directors

Orexo AB (publ), Annual General Meeting, Apr 26, 2024

Orexo AB (publ) Announces Data from the MODIA Study Evaluating Impact on Use of Illicit Opioids

Orexo AB (Publ) Announces Henrik Kjær Hansen Will Resign from the Board of Directors

Orexo AB (publ) to Report Q2, 2024 Results on Jul 17, 2024

Orexo AB (publ.) Submits New Drug Application to FDA for OX124, a High-Dose Rescue Medication for Opioid Over Overio Overio Overio Overio

Second quarter 2023 earnings released

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

First quarter 2023 earnings released

Orexo AB (publ) Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose

Full year 2022 earnings released: kr5.17 loss per share (vs kr6.51 loss in FY 2021)

Orexo AB (publ.) Initiates Exploratory Feasibility Studies of amorphOX with Two Leading Biopharmaceutical and Vaccine Companies

Orexo AB (publ) to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Third quarter 2022 earnings released

Orexo AB (publ) Announces Last Patient Enrolled in Pivotal Study Evaluating the Efficacy of MODIA® in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Orexo AB (publ) Appoints Edward Kim, M.D., as New Chief Medical Officer

Orexo AB (publ), Annual General Meeting, Apr 18, 2023

Orexo Announces Positive Data from Phase 1 Clinical Study for OX640

Orexo AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Second quarter 2022 earnings released

Orexo AB (Publ.) Announces Successfully Initiated the First Explorative Human Clinical Study for Ox640

First quarter 2022 earnings released

Orexo AB (publ) Announces Board Appointments

Full year 2021 earnings released: kr6.51 loss per share (vs kr2.45 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Orexo AB (publ) to Report Q4, 2022 Results on Jan 26, 2023

Orexo AB (Publ.) Develops Nasal Adrenaline Medication Based on the Novel Amorphox Platform

Orexo AB Provides Information About Its New Proprietary Drug Delivery Platform - Amorphox

Third quarter 2021 earnings released: kr1.52 loss per share (vs kr2.45 loss in 3Q 2020)

Second quarter 2021 earnings released: kr2.15 loss per share (vs kr0.94 loss in 2Q 2020)

Orexo AB (Publ) Pharmaceutical Pipeline Asset Ox124 Enters Pivotal Trial

Orexo Announces First Patient Enrolled in Pivotal Study Evaluating the Efficacy of Modia™ in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Independent Director recently bought €10k worth of stock

Independent Director recently bought €10k worth of stock

Independent Chairman of the Board recently bought €40k worth of stock

First quarter 2021 earnings released

Full year 2020 earnings released: kr2.45 loss per share (vs kr6.33 profit in FY 2019)

New 90-day low: €4.25

President & CEO recently bought €7.5k worth of stock

Orexo AB (publ) to Report Q3, 2021 Results on Nov 03, 2021

Orexo Starts to Test modiaT on Patients in Collaboration with Apexb.Io and Magellan Rx Management

Full year 2020 earnings released: kr2.45 loss per share (vs kr6.33 profit in FY 2019)

Revenue beats expectations

Orexo Strengthens IP Rights for Overdose Rescue Drug OX124

New 90-day high: €5.24

Orexo AB Enters into License and Supply Agreement with Accord Healthcare for ZUBSOLV

Revenue misses expectations

Orexo AB (Publ) Reaffirms Earnings Guidance for the Year of 2020

Orexo AB (publ) to Report Q1, 2021 Results on Apr 29, 2021

New 90-day low: €4.66

Orexo AB (publ) Announces Management Changes

New 90-day low - €4.92

New 90-day low - €5.59

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team